Hexima Ltd · ASX:HXL
Hexima — Switzer Small and Micro-Cap Virtual Investor Day (September 2021)
17 slides from Hexima's conference presentation, Sep 27, 2021
Slide 1: Hexima to present at Switzer Small and Micro-Cap Virtual Investor Day
ASX Announcement 27 September 2021 For personal use only Hexima to present at Switzer Small and Micro-Cap Virtual Investor Day MELBOURNE, AUSTRALIA (27 September 2021): Hexima Limited (ASX:HXL) is pleased to announce that Michael Aldridge, CEO will present on Tuesday 28 September at 9:25 AM (AEST) a
Slide 2: Hexima Limited: A game-changing treatment for onychomycosis
SEPTEMBER 2021 For personal use only HEXIMA LIMITED (ASX:HXL) A game-changing treatment for onychomycosis 1
Slide 3: Disclaimer
DISCLAIMER For personal use only Summary information events and the future financial performance of Hexima. Forward looking words such as “expect”, “should”, “could”, “may”, This presentation has been prepared by Hexima Ltd and its subsidiaries (collectively “Hexima”). The information in this “predi
Slide 4: Developing a novel topical product addressing a clear unmet need in a large and growing market
HEXIMA LIMITED (ASX:HXL) DE VE LOPING A NOVE L TOPIC A L PR ODUC T A DDR E S S ING A C L E A R UNME T NE E D IN A L A R GE A ND GR OWING MA R KE T For personal use only CLINICAL-STAGE, LARGE AND GROWING NOVEL, PROPRIETARY PEZADEFTIDE ADDRESSES WELL-DEFINED INFECTIOUS DISEASE-FOCUSED MARKET WITH SUBS
Slide 5: Pezadeftide in action
PEZADEFTIDE IN ACTION For personal use only Click to play animation C ON S UMER- C EN TRI C DEVELOPMEN T S LI DE 4
Slide 6: Existing therapies do not meet consumer needs
EXISTING THERAPIES DO NOT MEET CONSUMER NEEDS For personal use only C L E A R MA R K E T NE E D F OR A S A F E , C ONVE NIE NT A ND M OR E E F F E C TIVE TOPIC A L PR ODUC T TOPICAL Long treatments, ORAL DRUGS Better efficacy but potential TREATMENTS poor efficacy for serious adverse events Patients
Slide 7: Our solution: pezadeftide is a naturally occurring peptide
OUR SOLUTION: PEZADEFTIDE IS A NATURALLY OCCURRING PEPTIDE PEZADEFTIDE MOLECULE For personal use only ITS UNIQ UE PR OPE R TIE S E NA B L E R A PID NA IL PE NE TR A TION A ND F UNGA L KILLING Pezadeftide is a potent broad-spectrum antifungal peptide that has evolved to kill fungal pathogens • Hydrop
Slide 8: Successful phase I/IIa clinical trial
SUCCESSFUL PHASE I/IIA CLINICAL TRIAL 12 12 For personal use only HXP124-ONY-001 – TRIAL DESIGN WEEKS WEEKS Randomised, double blind, vehicle- COHORT 3 COHORT 4 controlled, ascending dose cohort study Pezadeftide 2% Pezadeftide 2% N=6 patients N=30 patients Patients treated nails daily with (randomi
Slide 9: Primary endpoint: safety and tolerability
PRIMARY ENDPOINT SAFETY AND TOLERABILITY For personal use only H X P124-ONY-0 0 1 – NO S YS TE M IC A B S OR PTION A ND NO LOC A L R E D NE S S OR IR R ITA TION Pezadeftide is safe and well tolerated NOLORD REM U GIPSU - R E LM ATED NNO O SSYY SSTT EMIC EMIC A D V EDOLOR RSE EVENTS TTO OXI XIC CIT I
Slide 10: Effective and rapid anti-fungal activity
EFFECTIVE AND RAPID ANTI-FUNGAL ACTIVITY For personal use only HXP124-ONY-001 – MYCOLOGICAL CURE RATE FOR COHORT 4 30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS Mycological Cure at 12 weeks 75.0% 69.0% Mycological cure* was achieved in 69% 60.0% of pezadeftide-treated nails in Cohort 4 within 12
Slide 11: Pezadeftide rapidly cleared the affected nail area
PEZADEFTIDE RAPIDLY CLEARED THE AFFECTED NAIL AREA For personal use only HXP124-ONY-001 – CLEAR NAIL GROWTH FOR COHORT 4 30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS Clinical Efficacy over time 15% 14% Pezadeftide cleared the affected nail Proportion of patients with area more effectively than
Slide 12: Rapid and dramatic improvement in appearance of nails
RAPID AND DRAMATIC IMPROVEMENT IN APPEARANCE OF NAILS Click to play animation NOTIC E A B LE IM PR OVE M E NT IN J US T 2 WE E KS , For personal use only A L MOS T C LE A R IN 12 W E E KS Pezadeftide penetrates the nail to kill the fungus, allowing healthy, uninfected nail to grow out • Clear nail g
Slide 13: Patent filed on CompliancePak and associated mobile application
PATENT FILED ON COMPLIANCEPAK ASSOCIATED MOBILE APPLICATION For personal use only CompliancePak Mobile App benefits & benefits & highlights highlights CompliancePak Mobile app • No spill / difficult to misplace • Reinforces FDA use directions (with video) • Easy to open / child resistant • Complianc
Slide 14: Potential to deliver the preferred solution in a consumer-driven market
POTENTIAL TO DELIVER THE PREFERRED SOLUTION IN A CONSUMER-DRIVEN MARKET For personal use only Convenient, Effective, Safe, topical short course of best-in-class medication therapy mycological cure FOR PATIENTS WHO WANT FOR PHYSICIANS WHO WANT FOR PAYERS WHO WANT An easy-to-apply topical An effective
Slide 15: Australian phase IIb clinical trial
AUSTRALIAN PHASE IIB CLINICAL TRIAL H X P124-ONY-0 0 2 Enrolment For personal use only completed WEEK WEEK WEEK WEEK July 2021 13 24 36 40 • Multi-center, randomised, double blind, 12 WEEK DA I LY DOS I N G vehicle-controlled study • Primary endpoint safety and tolerability, 12 WEEK DA I L Y DOS I N
Slide 16: Pezadeftide: a potential solution for a large and poorly served market
PEZADEFTIDE: A POTENTIAL SOLUTION FOR A LARGE AND POORLY SERVED MARKET For personal use only POORLY SERVED MARKET NEW AND UNIQUE SAFE CONVENIENT EFFECTIVE Affects 14% of the Novel molecule with No systemic effects Easy to apply Efficiently penetrates population unique mode of action the nail No loca
Slide 17: Contacts
CONTACTS For personal use only M IC HAEL D R N IC O LE ALD RIDGE V AN D E R W E ERD E N C H IE F E X E C UTIVE OF F IC E R C H IE F OPE R A TING OF F IC E R m.aldridge@hexima.com.au n.vanderweerden@hexima.com.au hexima.com.au +1 650 452 4684 +61 407 039 983 C ORPORA TE PRES EN TA TI ON S LI DE 16
Hexima — Switzer Small and Micro-Cap Virtual Investor Day (September 2021) on 6ix